FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2782645260> ?p ?o ?g. }

• W2782645260 endingPage "120" @default.
• W2782645260 startingPage "119" @default.
• W2782645260 abstract "Yoshino et al [ [1] Yoshino T. Obermannova R. Bodoky G. Garcia-Carbonero R. Ciuleanu T. Portnoy D.C. et al. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. Eur J Cancer. 2017; 78: 61-69 Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar ] recently reported results from the RAISE trial(completed phase 3, NCT01183780), in which 1072 metastatic colorectal cancer patients were treated with ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGF-R2). They observed that low baseline serum levels of carcinoembryonic antigen (CEA) were associated with longer overall survival (OS) and progression-free survival (PFS). However, the authors did not discuss the possible mechanisms behind this association although the published literature may provide an answer. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trialEuropean Journal of CancerVol. 78PreviewThe RAISE phase III clinical trial demonstrated that ramucirumab + (folinic acid plus 5-fluorouracil plus irinotecan) FOLFIRI significantly improved overall survival (OS) versus placebo + FOLFIRI for second-line metastatic colorectal carcinoma (mCRC) patients failing bevacizumab- and oxaliplatin-based chemotherapy (hazard ratio [HR] = 0.84, 95% CI = 0.73–0.98, P = 0.022). Post hoc analyses of RAISE patient data examined the association of carcinoembryonic antigen (CEA) subgroups with efficacy parameters. Full-Text PDF Open AccessResponse to Letter to the Editor, ‘Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,’ by Ibrahim et al.European Journal of CancerVol. 92PreviewIn recent correspondence to the Editor (‘Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab’) [1], Ibrahim et al. commented on our paper, ‘Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial’ [2]. The authors rightly observed that our data showed that low baseline serum levels of carcinoembryonic antigen (CEA) were associated with longer overall (OS) and progression-free survival. Full-Text PDF" @default.
• W2782645260 created "2018-01-26" @default.
• W2782645260 creator A5001067418 @default.
• W2782645260 creator A5033266569 @default.
• W2782645260 creator A5039278929 @default.
• W2782645260 creator A5061600476 @default.
• W2782645260 creator A5084815041 @default.
• W2782645260 date "2018-03-01" @default.
• W2782645260 modified "2023-09-25" @default.
• W2782645260 title "Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab" @default.
• W2782645260 cites W1968504912 @default.
• W2782645260 cites W2017560551 @default.
• W2782645260 cites W2051615897 @default.
• W2782645260 cites W2073296841 @default.
• W2782645260 cites W2079852644 @default.
• W2782645260 cites W2171945667 @default.
• W2782645260 cites W2423724319 @default.
• W2782645260 cites W2606127401 @default.
• W2782645260 cites W2737853832 @default.
• W2782645260 cites W4289258260 @default.
• W2782645260 doi "https://doi.org/10.1016/j.ejca.2017.12.004" @default.
• W2782645260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29329696" @default.
• W2782645260 hasPublicationYear "2018" @default.
• W2782645260 type Work @default.
• W2782645260 sameAs 2782645260 @default.
• W2782645260 citedByCount "3" @default.
• W2782645260 countsByYear W27826452602018 @default.
• W2782645260 countsByYear W27826452602019 @default.
• W2782645260 countsByYear W27826452602021 @default.
• W2782645260 crossrefType "journal-article" @default.
• W2782645260 hasAuthorship W2782645260A5001067418 @default.
• W2782645260 hasAuthorship W2782645260A5033266569 @default.
• W2782645260 hasAuthorship W2782645260A5039278929 @default.
• W2782645260 hasAuthorship W2782645260A5061600476 @default.
• W2782645260 hasAuthorship W2782645260A5084815041 @default.
• W2782645260 hasBestOaLocation W27826452602 @default.
• W2782645260 hasConcept C121608353 @default.
• W2782645260 hasConcept C126322002 @default.
• W2782645260 hasConcept C143998085 @default.
• W2782645260 hasConcept C2776694085 @default.
• W2782645260 hasConcept C2776705615 @default.
• W2782645260 hasConcept C2777387746 @default.
• W2782645260 hasConcept C2777802072 @default.
• W2782645260 hasConcept C2778260052 @default.
• W2782645260 hasConcept C2779551604 @default.
• W2782645260 hasConcept C2779998722 @default.
• W2782645260 hasConcept C2780259306 @default.
• W2782645260 hasConcept C2780962732 @default.
• W2782645260 hasConcept C526805850 @default.
• W2782645260 hasConcept C71924100 @default.
• W2782645260 hasConcept C90924648 @default.
• W2782645260 hasConceptScore W2782645260C121608353 @default.
• W2782645260 hasConceptScore W2782645260C126322002 @default.
• W2782645260 hasConceptScore W2782645260C143998085 @default.
• W2782645260 hasConceptScore W2782645260C2776694085 @default.
• W2782645260 hasConceptScore W2782645260C2776705615 @default.
• W2782645260 hasConceptScore W2782645260C2777387746 @default.
• W2782645260 hasConceptScore W2782645260C2777802072 @default.
• W2782645260 hasConceptScore W2782645260C2778260052 @default.
• W2782645260 hasConceptScore W2782645260C2779551604 @default.
• W2782645260 hasConceptScore W2782645260C2779998722 @default.
• W2782645260 hasConceptScore W2782645260C2780259306 @default.
• W2782645260 hasConceptScore W2782645260C2780962732 @default.
• W2782645260 hasConceptScore W2782645260C526805850 @default.
• W2782645260 hasConceptScore W2782645260C71924100 @default.
• W2782645260 hasConceptScore W2782645260C90924648 @default.
• W2782645260 hasLocation W27826452601 @default.
• W2782645260 hasLocation W27826452602 @default.
• W2782645260 hasLocation W27826452603 @default.
• W2782645260 hasLocation W27826452604 @default.
• W2782645260 hasOpenAccess W2782645260 @default.
• W2782645260 hasPrimaryLocation W27826452601 @default.
• W2782645260 hasRelatedWork W132389072 @default.
• W2782645260 hasRelatedWork W1792988773 @default.
• W2782645260 hasRelatedWork W1991332977 @default.
• W2782645260 hasRelatedWork W2077546410 @default.
• W2782645260 hasRelatedWork W2134986421 @default.
• W2782645260 hasRelatedWork W2589212911 @default.
• W2782645260 hasRelatedWork W2591743724 @default.
• W2782645260 hasRelatedWork W2802627520 @default.
• W2782645260 hasRelatedWork W2939662662 @default.
• W2782645260 hasRelatedWork W4255693185 @default.
• W2782645260 hasVolume "92" @default.
• W2782645260 isParatext "false" @default.
• W2782645260 isRetracted "false" @default.
• W2782645260 magId "2782645260" @default.
• W2782645260 workType "article" @default.